<DOC>
	<DOCNO>NCT01235117</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , azacitidine , work different way stop growth cancer cell , either kill cell stop dividing . PURPOSE : This phase II trial study side effect azacitidine see well work treat patient chronic myelomonocytic leukemia .</brief_summary>
	<brief_title>Azacitidine Treating Patients With Chronic Myelomonocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess safety tolerability azacitidine patient chronic myelomonocytic leukemia ( CMML ) . - To assess overall response rate patient . Secondary - To assess incidence clinical remission/complete remission partial response patient . - To assess hematological improvement patient treat drug . - To assess overall survival patient treated drug . - To assess progression-free survival patient treated drug . - To assess time acute myeloid leukemia ( AML ) transformation CMML . - To assess time death AML transformation CMML . - To assess biological correlate . OUTLINE : This multicenter study . Patients receive azacitidine subcutaneously day 1-5 8-9 . Treatment repeat every 4 week least 6 course absence loss response/disease progression unacceptable toxicity . Patients undergo response evaluation 6 course last course treatment . Responders may continue azacitidine loss response/disease progression unacceptable toxicity . Some patient undergo blood , bone marrow , buccal swab sample collection periodically correlative study . After completion study treatment , patient follow 1 month . Peer Reviewed Funded Endorsed Cancer Research UK</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : All chronic myelomonocytic leukemia ( CMML ) 2 patient CMML1 patient meet follow criterion : Symptomatic bone marrow failure/myeloproliferation define follow : Red cell transfusion dependence pretransfusion hemoglobin &lt; 9.0 g/dL Symptomatic anemia ( hemoglobin &lt; 11.5 g/dL ) Thrombocytopenia ( platelet count &lt; 50 x 10^9/L ) Symptomatic bleeding due platelet functional defect disseminate intravascular coagulation ( DIC ) /fibrinolysis White cell count ( WCC ) &gt; 50 x 10^9/L Düsseldorf Score intermediate high risk proliferative CMML1 ( i.e. , WCC &gt; 12 x 10^9/L ) International Prognostic Scoring System ( IPSS ) score intermediate2 high risk nonproliferative CMML1 ( i.e. , WCC &lt; 12 x 10^9/L ) Systemic symptom include weight loss alternative explanation ( 10 % baseline weight within past 6 month ) Symptomatic splenomegaly Symptomatic extramedullary involvement ( e.g . skin infiltration serous effusion ) No CMML eosinophilia 5q33 abnormality PATIENT CHARACTERISTICS : WHO performance status 02 Creatinine ≤ 2 time upper limit normal Not pregnant nursing Negative urine pregnancy test Fertile patient must use least 2 form effective contraception study 3 month completion study therapy No active malignant disease include basal cell squamous cell carcinoma skin No known HIV infectious hepatitis B hepatitis C No active infection No known hypersensitivity azacitidine mannitol PRIOR CONCURRENT THERAPY : At least 28 day since prior experimental drug therapy No prior chemotherapy disease except hydroxycarbamide No concurrent anticancer investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>chronic myelomonocytic leukemia</keyword>
</DOC>